Senses Disorder TRIZ Cases

NMDA receptor blockade with neramexane helps relieve hearing loss and tinnitus while improving efficacy through dosage and release formulation choices.

Cyclopentane-based ocular hypotensive compounds lower intraocular pressure by promoting aqueous humor drainage while addressing limits of beta blockers.

Gradual neramexane dose escalation reaches an effective tinnitus treatment level while limiting adverse events through a structured multi-dose package.

Targeting both NMDA and α9/α10 nicotinic receptors, neramexane reduces cochlear tinnitus and annoyance linked to hearing loss.

Gradual neramexane dose escalation with multi-dose packaging reaches effective tinnitus treatment levels while limiting side effects.

Novel substituted cyclopentanes use modular functional-group changes to lower intraocular pressure and broaden glaucoma treatment options.

Dual NMDA and α9/α10 receptor antagonism addresses afferent and efferent imbalance to reduce sub-acute cochlear tinnitus severity and annoyance.

Upstream MASP-3 binding blocks alternative complement activation while preserving the classical pathway, reducing hemolysis and C3b deposition.

High-affinity MASP-3 antibodies block alternative pathway initiation, reducing hemolysis, C3 cleavage, and C3b deposition.

Mini-tablets and granules with an amorphous solid dispersion improve pediatric dosing accuracy, administration, and drug delivery in cystic fibrosis.

A p62 ZZ-domain ligand activates selective autophagy to clear misfolded protein aggregates without disrupting mTOR-regulated pathways.

Local photodynamic activation boosts systemically delivered photosensitive antibiotics at infected tissue, improving action against resistant microbes.

Biomarker panels distinguish infectious from noninfectious uveitis and identify bacterial, viral, or fungal causes without culture delays.

Intravenous anti-CGRP antibodies inhibit CGRP to relieve migraine within hours and reduce attack frequency with sustained dosing.

Pyridine derivatives disrupt sortilin binding with pro-neurotrophins or p75NTR to block apoptotic complex formation and improve treatment safety.

New sequence-defined aptamers neutralize GPCR autoantibodies and support therapy, diagnosis, and apheresis for autoimmune disease.

Deuterated water helps low-dose atropine eye drops resist hydrolysis, maintain potency, and reduce side effects over long storage.

Oral protease-degraded comb extract improves dry eye, ocular pain, vision, and intraocular pressure without eye-drop burden or preservative risks.

Gold nanorods convert near-infrared light into heat to open engineered retinal TRP channels, restoring visual responses without electrodes.

Dual VEGF and ANG-2 intravitreal dosing controls ocular vascular disease while extending retreatment intervals and limiting systemic exposure.

A buffered anti-IL-4R antibody liquid formulation uses stabilizers and viscosity reducers to limit aggregation and support convenient administration.

Transient reprogramming factors and chromatin remodeling convert somatic cells into stable neural stem-like cells without teratoma risk.

A Formula (I) PDE IV inhibitor suppresses inflammatory cytokine release to treat inflammatory and other PDE IV-mediated conditions.

A Bacteroides α-fucosidase removes core fucose from N-linked glycans under mild conditions, enabling glycoprotein defucosylation without denaturation.

Slow-release DNP prodrugs use sustained low-dose mitochondrial uncoupling to address disease progression while limiting toxicity.

Helix 6 mutations at positions 218 and 220 reduce light-dependent desensitization while sustaining photocurrents at lower, less phototoxic light levels.

A cation-then-anion exchange sequence refines aflibercept across a broad isoelectric range to improve purity and yield for ophthalmic use.

Quaternary blockers enter large-pore channels to selectively inhibit nociceptors, easing pain, itch, cough, and inflammation with fewer side effects.

A 1,3-dioxane modulator case showing how eIF2B stabilization can tune the integrated stress response with better selectivity and pharmacokinetics.

Irradiated UCMSCs on a silicone hydrogel lens stay longer on the eye, enabling local immunomodulation for oGVHD without systemic side effects.

A modified rAAV capsid and cone-specific expression cassette improve intravitreal gene delivery to retinal cones in the fovea.

Small molecules that inhibit Lats kinases and activate Yap signaling promote supporting-cell proliferation and inner ear hair-cell regeneration.

Mesenchymal stem cell secretions promote epithelial differentiation and tight junction formation to improve barrier function in dry eye and related diseases.

Targeting Asgr1 and Clec10a with a ligand composition helps suppress TLR4-driven allergic responses caused by house dust mites.

Ang1-high stem cells modulate macrophages and cytokines to treat diabetes while avoiding lifelong immunosuppression.

Timed Noggin withdrawal in dual-SMAD induction shifts human pluripotent stem cells from CNS fates to cranial placodes for sensory and endocrine cell production.

A sequential three-agent protocol with cell culture robots cuts operator variability and supports scalable, high-purity RPE cell production.

Low-dose 5-HT2A agonist and NMDAR-modulating formulations promote neural plasticity without psychedelic effects, enabling repeatable therapy.

Feeder-free pluripotent stem cell culture uses Sonic hedgehog and BMP activation to form uniform aggregates for efficient retinal tissue production.

Specific syndecan-2 peptide fragments inhibit endothelial migration and tubule formation to suppress angiogenesis with fewer side effects.

Annelid hemoglobin improves oxygen delivery to corneal endothelial cells, reducing hypoxia stress markers linked to Fuchs' disease.

Hydrogel-forming polymers extend precorneal residence time while keeping eyedrops low-viscosity, comfortable, and less frequently applied.

Novel oxopyridazinyl dicyanide compounds inhibit tau aggregation and hyperphosphorylation while avoiding cytotoxicity in tauopathy treatment.

Helix-6 mutations at positions 218 and 220 cut light-dependent desensitization, sustaining photocurrents at lower light intensities.

Vitis vinifera leaf extract offers a food or pharmaceutical approach to relieve noise-induced tinnitus when standard options show limited benefit.

Low molecular weight DLK/LZK inhibitors provide neuroprotection to reduce neuronal cell death and vision loss in ophthalmic disorders.

Compounds that modulate PLXDC1/PLXDC2 kill existing pathogenic blood vessels, complementing anti-angiogenic therapy while sparing healthy vessels.

CRISPR-based PLP1 modification lowers toxicity while restoring functional myelin production and improving neurological outcomes.

Engineered mesenchymal stem cells secrete FGF21 and GLP-1 to lower glucose and lipids without long-term drug administration.

Dual-binding antibodies target fibrin γC and VEGF to curb microglial activation and angiogenesis while preserving coagulation in eye disorders.

A dual-path nitric oxide composition pairs NOS-dependent and NOS-independent sources with MPO inhibition to raise NO quickly and limit oxidative loss.

Fused bridgehead azole scaffolds improve SHP2 potency, residence time, plasma exposure, and blood-brain barrier penetration for CNS tumors.

Pupil and accommodation measurements are used to estimate ocular drug penetration and receptor blockade for personalized myopia dosing.

Pre-mRNA trans-splicing corrects OPA1 mutations while preserving endogenous isoform regulation, aiming to restore vision with minimal mitochondrial disruption.

A dual 5-HT2A antagonist and CYP2D6 inhibitor boosts dextromethorphan exposure to reduce dementia agitation and psychosis with fewer adverse effects.

An in vivo crosslinking hydrogel in the suprachoroidal space lowers intraocular pressure for months without daily drops or surgery.

Targeting FosB/ΔFosB, VCAM-1, and ERK1/2 helps reduce vascular leakage, angiogenesis, inflammation, and poor response to existing therapies.

Metal-modified cerium oxide nanoparticles help infected wounds heal faster by reducing inflammation while destroying bacteria and viruses.

Small ABCA1-stabilizing peptides restore retinal lipid transport, clear drusen lipids, and address dry and wet AMD progression.

By recruiting androgen receptors to E3 ubiquitin ligases, these bifunctional compounds drive AR degradation to address resistance and side effects.

Controlling aflibercept truncation variants to 20% or less preserves activity while avoiding extra purification, time, and cost.

Selective amide-substituted aromatic compounds inhibit TYK2 to treat autoimmune inflammation while avoiding broad JAK-related side effects.

Odd-chain lipids such as tripentadecanoin protect neurons, limit apoptosis, and support axon regrowth in degenerative disorders.

A stable oil-in-water THC eye emulsion improves solubility, tolerability, and sustained intraocular pressure reduction for glaucoma.

Cyclizing prosaposin peptides improves serum stability and Tsp-1 stimulation, enabling lower-toxicity treatment of cancer and inflammatory disease.

A purified young-animal plasma fraction uses PEG and size-based separation to deliver anti-aging effects without donor scarcity or immune response.

A resistive heated, airflow-permeable cartridge vaporizes botanical doses at controlled temperature while preserving microstructure and flow consistency.

C3-disubstituted 19-nor steroids improve oral bioavailability and dose response while modulating GABA receptors for CNS disorders.

A multivalent antibody links FZD4, LRP5, and VEGF binding to activate Wnt/β-catenin signaling without hard-to-purify Wnt proteins.

Ocular lutein and zeaxanthin help protect foveal architecture and eyeball shape in children facing prolonged screen time and near work.

Cell-reactive and targeted compstatin analogs attach to cells or tissues to extend complement inhibition and reduce repeated treatments.

Directed small-molecule differentiation produces high-purity RPE cells in 30 days without manual selection or animal-derived components.

A semi-permeable intraocular capsule sustains local biologic release for at least 12 months while avoiding long-term immunosuppression.

A low-volume cryopreservative blend enables wash-free thawing, reducing cell loss and damage while preserving post-thaw viability.

A gp130-Fc polypeptide dimer selectively blocks IL-6 trans-signalling while preserving classic signalling and normal blood counts.

Upstream MASP-2 and MASP-3 inhibition blocks complement initiation to reduce tissue damage and inflammation beyond C5-targeted therapy.

AAV1 capsids enable pan-tropic transduction across inner ear cell types in primate models, supporting gene therapy for hearing and vestibular disorders.

An anhydrous semi-solid base keeps selenium disulfide uniformly dispersed without surfactants, reducing aggregation and ocular surface interaction.

Controlled-size PLGA peptide granules improve shelf-life and drug loading while sustaining intraocular anti-inflammatory release.

Reducing tmytC expression weakens Tsukamurella biofilm and adherence, enabling PHMB-based treatment to lower corneal infection severity.

IFN-γ anterior chamber injection creates a stable open-angle glaucoma model by impairing trabecular meshwork function without structural disruption.

Carbachol eye drops stimulate the ciliary muscle to temporarily improve near vision and relieve presbyopia without surgery or lenses.

Targeting VEGF and TGF-beta pathways with selective multi-kinase inhibitors helps reduce chronic inflammation, angiogenesis, and fibrosis.

Targeted peptide-magnetic conjugates bind and extract exfoliation deposits from the eye to stabilize intraocular pressure and help prevent glaucoma.

A PRP-based eye drop combines cyclosporine, hyaluronic acid, and antioxidants to relieve dry eye and protect the corneal surface.

AAV-mediated DFNB59 transfer improves inner ear gene delivery to restore auditory nerve signaling and reduce neuron degeneration in ANSD.

Splitting OTOF cDNA across two AAV vectors enables in vivo recombination, restoring Otoferlin expression and hearing in DFNB9.

Norrin activates Wnt signaling to raise claudin-5 and VE-cadherin expression, reducing retinal vascular leakage and edema.

rAAV delivery of GABA receptor subunits restores inhibitory synapses in auditory cortex and improves hearing-related perception deficits.

Floating culture in defined media replaces basement membrane preparations to produce retinal progenitor cells with higher purity and lower contamination risk.

Hydroxypropyl beta-cyclodextrin keeps A-5021 soluble at neutral pH, enabling stable eye drops for ocular herpes diagnosis and treatment.

A stable water-in-silicone emulsion extends vulvovaginal symptom relief while supporting pH balance, tissue protection, and drug delivery.